Cargando…

Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences

Metformin is the most widely prescribed drug to treat patients with type II diabetes, for whom retrospective studies suggest that metformin may have anticancer properties. However, in experiments performed with isolated cells, authors have reported both pro- and anti-apoptotic effects of metformin....

Descripción completa

Detalles Bibliográficos
Autor principal: Fontaine, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304344/
https://www.ncbi.nlm.nih.gov/pubmed/30619086
http://dx.doi.org/10.3389/fendo.2018.00753
_version_ 1783382338546171904
author Fontaine, Eric
author_facet Fontaine, Eric
author_sort Fontaine, Eric
collection PubMed
description Metformin is the most widely prescribed drug to treat patients with type II diabetes, for whom retrospective studies suggest that metformin may have anticancer properties. However, in experiments performed with isolated cells, authors have reported both pro- and anti-apoptotic effects of metformin. The exact molecular mechanism of action of metformin remains partly unknown despite its use for over 60 years and more than 17,000 articles in PubMed. Among the various widely recognized or recently proposed targets, it has been reported consistently that metformin is capable of inhibiting mitochondrial respiratory chain Complex I. Since most of the effects of metformin have been replicated by other inhibitors of Complex I, it has been suggested that the mechanism of action of metformin involved the inhibition of Complex I. However, compared to conventional Complex I inhibitors, the metformin-induced inhibition of Complex I has unique characteristics. Among these, the most original one is that the concentrations of metformin required to inhibit Complex I are lower in intact cells than in isolated mitochondria. Experiments with isolated mitochondria or Complex I were generally performed using millimolar concentrations of metformin, while plasma levels remain in the micromolar range in both human and animal studies, highlighting that metformin concentration is an important issue. In order to explain the effects in animals based on observations in cells and mitochondria, some authors proposed a direct effect of the drug on Complex I involving an accumulation of metformin inside the mitochondria while others proposed an indirect effect (the drug no longer having to diffuse into the mitochondria). This brief review attempts to: gather arguments for and against each hypothesis concerning the mechanism by which metformin inhibits Complex I and to highlight remaining questions about the toxicity mechanism of metformin for certain cancer cells.
format Online
Article
Text
id pubmed-6304344
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63043442019-01-07 Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences Fontaine, Eric Front Endocrinol (Lausanne) Endocrinology Metformin is the most widely prescribed drug to treat patients with type II diabetes, for whom retrospective studies suggest that metformin may have anticancer properties. However, in experiments performed with isolated cells, authors have reported both pro- and anti-apoptotic effects of metformin. The exact molecular mechanism of action of metformin remains partly unknown despite its use for over 60 years and more than 17,000 articles in PubMed. Among the various widely recognized or recently proposed targets, it has been reported consistently that metformin is capable of inhibiting mitochondrial respiratory chain Complex I. Since most of the effects of metformin have been replicated by other inhibitors of Complex I, it has been suggested that the mechanism of action of metformin involved the inhibition of Complex I. However, compared to conventional Complex I inhibitors, the metformin-induced inhibition of Complex I has unique characteristics. Among these, the most original one is that the concentrations of metformin required to inhibit Complex I are lower in intact cells than in isolated mitochondria. Experiments with isolated mitochondria or Complex I were generally performed using millimolar concentrations of metformin, while plasma levels remain in the micromolar range in both human and animal studies, highlighting that metformin concentration is an important issue. In order to explain the effects in animals based on observations in cells and mitochondria, some authors proposed a direct effect of the drug on Complex I involving an accumulation of metformin inside the mitochondria while others proposed an indirect effect (the drug no longer having to diffuse into the mitochondria). This brief review attempts to: gather arguments for and against each hypothesis concerning the mechanism by which metformin inhibits Complex I and to highlight remaining questions about the toxicity mechanism of metformin for certain cancer cells. Frontiers Media S.A. 2018-12-17 /pmc/articles/PMC6304344/ /pubmed/30619086 http://dx.doi.org/10.3389/fendo.2018.00753 Text en Copyright © 2018 Fontaine. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Fontaine, Eric
Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
title Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
title_full Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
title_fullStr Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
title_full_unstemmed Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
title_short Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences
title_sort metformin-induced mitochondrial complex i inhibition: facts, uncertainties, and consequences
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304344/
https://www.ncbi.nlm.nih.gov/pubmed/30619086
http://dx.doi.org/10.3389/fendo.2018.00753
work_keys_str_mv AT fontaineeric metformininducedmitochondrialcomplexiinhibitionfactsuncertaintiesandconsequences